Bryn Mawr Trust Advisors LLC Takes Position in Gilead Sciences, Inc. $GILD

Bryn Mawr Trust Advisors LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,368 shares of the biopharmaceutical company’s stock, valued at approximately $552,000.

Several other institutional investors also recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC increased its holdings in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC increased its holdings in shares of Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider directly owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock valued at $6,568,860 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 0.2%

Shares of GILD opened at $138.36 on Friday. The company has a market capitalization of $171.56 billion, a price-to-earnings ratio of -51.82 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The stock’s 50-day moving average price is $130.11 and its 200-day moving average price is $136.45. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on GILD shares. Rothschild & Co Redburn lowered their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Finally, Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Twenty-four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.